Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.
Stevens, K.L., Reno, M.J., Alberti, J.B., Price, D.J., Kane-Carson, L.S., Knick, V.B., Shewchuk, L.M., Hassell, A.M., Veal, J.M., Davis, S.T., Griffin, R.J., Peel, M.R.(2008) Bioorg Med Chem Lett 18: 5758-5762
- PubMed: 18835709 
- DOI: https://doi.org/10.1016/j.bmcl.2008.09.069
- Primary Citation of Related Structures:  
3EID, 3EJ1 - PubMed Abstract: 
A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.
Organizational Affiliation: 
Department of Oncology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. Kirk.L.Stevens@gsk.com